May 3, 2006
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
DELAWARE | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
ITEM 7.01. Regulation FD Disclosure
On May 3, 2006 Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a national leader in pharmacogenetic testing, announced that it has begun offering a personalized drug response interpretation service for cytochrome P450 (CYP450) testing called Signature Genetics to complement its expanding menu of genetic tests for CYP450 mutations. The Signature Genetics service helps physicians use CYP450 genotyping information to make tailored treatment decisions based on an individual patients CYP450 testing results.
Exhibits
99.1 Press Release dated May 3, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Laboratory Corporation of America Holdings (Registrant) |
||||
Date: May 3, 2006 | By: | /s/Bradford T. Smith | ||
Bradford T. Smith, Executive Vice President and Secretary |
||||